查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947838

AR T细胞疗法市场分析及预测（至2035年）：按类型、产品类型、服务、技术、应用、最终用户、流程、实施、阶段和解决方案划分

AR T-Cell therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Deployment, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 349 Pages | 商品交期: 3-5个工作天内

价格
简介目录

抗原受体（AR）T细胞疗法市场预计将从2024年的48亿美元成长到2034年的368亿美元，复合年增长率约为33%。 AR T细胞疗法市场涵盖了利用抗原受体进行精准标靶化的先进免疫疗法，这些疗法透过改造T细胞来识别并攻击癌细胞。基因工程和个人化医疗领域的创新是推动该市场成长的主要动力，旨在提高治疗效果并降低復发率。癌症发病率的上升和生物技术领域投资的增加正在推动市场成长，而重点在于拓展适应症和提高安全性。

受个人化医疗和免疫疗法发展趋势的推动，AR T细胞疗法市场正经历强劲成长。肿瘤领域是成长最快的领域，这主要得益于癌症发生率的上升和对标靶治疗需求的不断增长。在肿瘤领域，白血病和淋巴瘤等骨髓恶性肿瘤占据了主要细分市场，并受益于其高疗效。固体癌目前处于次要地位，但随着研究的进展和现有挑战的克服，其成长势头正在增强。非肿瘤领域，主要关注自体免疫疾病和感染疾病，是成长第二快的领域。 T细胞工程和扩增技术的创新正在提高疗效和安全性。尤其是在多发性硬化症和类风湿性关节炎等自体免疫疾病方面，已展现出令人鼓舞的成果，促使更多投资涌入。感染疾病领域，主要关注病毒感染疾病，也是AR T细胞疗法的一个极具潜力的应用领域。策略联盟和不断增加的临床试验正在加速市场发展，为相关人员提供了盈利的机会。

市场区隔
按类型 自体T细胞疗法、异体T细胞疗法
产品 CAR-T细胞疗法、TIL（肿瘤浸润淋巴细胞）疗法、TCR（T细胞受体）疗法
服务 临床试验服务、生产製造服务、物流与供应链服务、咨询服务
科技 基因编辑、CRISPR、慢病毒载体、逆转录病毒载体
应用领域 肿瘤学、血液学、固态肿瘤、感染疾病
最终用户 医院、癌症研究机构、生物製药公司、学术研究机构
过程 细胞分离、细胞活化、基因修饰、细胞增殖
实施表格 内部、外包
步 研究、临床试验和商业化
解决方案 个人化医疗，现成产品

AR T细胞疗法市场呈现动态变化的格局，市占率多元化，定价策略竞争激烈，新产品层出不穷。主要企业正利用创新方法拓展市场份额，同时保持价格竞争力，确保产品的可及性和市场渗透率。新型治疗方法的推出推动了市场成长，各公司优先考虑策略性产品发布，以最大限度地扩大其影响力。这种不断变化的市场格局凸显了市场致力于推动治疗方案、满足未被满足的医疗需求的努力。竞争基准分析显示，主要企业透过策略联盟和併购争夺主导，竞争异常激烈。监管影响至关重要，严格的指导方针影响市场准入和研发时间表。美国和欧洲仍处于领先地位，制定的监管标准塑造全球市场格局。然而，新兴市场及其不断发展的法规结构蕴藏着尚未开发的机会。在技​​术进步和研发投入不断增加的推动下，该市场蓄势待发，即将迎来成长。

主要趋势和驱动因素：

受生物技术和个人化医疗进步的推动，AR T细胞疗法市场正经历强劲成长。一个关键趋势是，人们越来越关注根据个别患者情况量身定制的精准医疗，以提高治疗效果并最大限度地减少副作用。基因工程和合成生物学的突破性进展为这一趋势提供了支持，使更具针对性和有效性的治疗方法成为可能。癌症和其他慢性疾病的日益普遍是推动市场成长的关键因素，促使人们对AR T细胞疗法等创新治疗方法的需求不断增长。此外，监管机构认识到这些疗法在满足未被满足的医疗需求方面的潜力，正在积极推动加快核准流程。这种监管支持营造了有利于快速创新和商业化的环境。对研发的投资也是一个关键驱动因素，公共和私营部门都投入了大量资源用于AR T细胞疗法计划。生物技术公司与学术机构之间的合作正在加速发现和开发的步伐。此外，新兴市场不断扩大的医疗基础设施正在开闢新的市场进入途径，为那些能够满足日益增长的先进治疗解决方案需求的公司提供了盈利机会。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 自体T细胞疗法
    • 同种异体T细胞疗法
  • 市场规模及预测：依产品划分
    • CAR T 细胞
    • 肿瘤浸润淋巴细胞（TILs）
    • TCR（T细胞受体）疗法
  • 市场规模及预测：依服务划分
    • 临床试验服务
    • 製造服务
    • 物流和供应链服务
    • 咨询服务
  • 市场规模及预测：依技术划分
    • 基因编辑
    • CRISPR
    • 慢病毒载体
    • 逆转录病毒载体
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 血液学
    • 固态肿瘤
    • 感染疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症研究所
    • 生物製药公司
    • 学术研究机构
  • 市场规模及预测：依製程划分
    • 细胞分离
    • 细胞活化
    • 基因改造
    • 细胞增殖
  • 市场规模及预测：依发展状况
    • 内部
    • 外包
  • 市场规模及预测：依阶段划分
    • 调查
    • 临床试验
    • 商业化
  • 市场规模及预测：按解决方案划分
    • 个人化医疗
    • 现成产品

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Adaptimmune Therapeutics
  • Atara Biotherapeutics
  • Autolus Therapeutics
  • Bellicum Pharmaceuticals
  • Cellectis
  • Celyad Oncology
  • Fate Therapeutics
  • Genocea Biosciences
  • Iovance Biotherapeutics
  • Kiadis Pharma
  • Kite Pharma
  • Marker Therapeutics
  • Mustang Bio
  • Poseida Therapeutics
  • Precision Bio Sciences
  • Sorrento Therapeutics
  • Tessa Therapeutics
  • Tmunity Therapeutics
  • Triumvira Immunologics
  • ZIOPHARM Oncology

第九章：关于我们

简介目录
Product Code: GIS31609

AR T-Cell therapy Market is anticipated to expand from $4.8 billion in 2024 to $36.8 billion by 2034, growing at a CAGR of approximately 33%. The AR T-Cell Therapy Market encompasses advanced immunotherapies that engineer T-cells to recognize and attack cancer cells, leveraging antigen receptors for precision targeting. This market is driven by innovations in genetic engineering and personalized medicine, aiming to enhance treatment efficacy and reduce relapse rates. Rising cancer prevalence and increasing investment in biotechnology are propelling growth, with a focus on expanding indications and improving safety profiles.

The AR T-Cell Therapy Market is experiencing robust growth, fueled by advancements in personalized medicine and immunotherapy. The oncology segment is the top performer, driven by the increasing prevalence of cancer and the need for targeted therapies. Within oncology, hematologic malignancies such as leukemia and lymphoma are leading sub-segments, benefiting from high efficacy rates. Solid tumors, although currently secondary, are gaining momentum as research overcomes existing challenges. The non-oncology segment, focusing on autoimmune diseases and infectious diseases, is the second-highest performing area. Innovations in T-cell engineering and expansion techniques are enhancing efficacy and safety profiles. Autoimmune disorders, particularly multiple sclerosis and rheumatoid arthritis, are showing promising results, spurring further investment. The infectious disease sub-segment, with a focus on viral infections, is also emerging as a viable area for AR T-Cell applications. Strategic collaborations and increasing clinical trials are accelerating market evolution, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeAutologous T-Cell Therapy, Allogeneic T-Cell Therapy
ProductCAR T-Cells, TILs (Tumor Infiltrating Lymphocytes), TCR (T-Cell Receptor) Therapy
ServicesClinical Trial Services, Manufacturing Services, Logistics and Supply Chain Services, Consulting Services
TechnologyGene Editing, CRISPR, Lentiviral Vectors, Retroviral Vectors
ApplicationOncology, Hematology, Solid Tumors, Infectious Diseases
End UserHospitals, Cancer Research Institutes, Biopharmaceutical Companies, Academic and Research Institutes
ProcessCell Isolation, Cell Activation, Gene Modification, Cell Expansion
DeploymentIn-house, Outsourced
StageResearch, Clinical Trials, Commercialization
SolutionsPersonalized Medicine, Off-the-shelf Products

The AR T-Cell therapy market is characterized by a dynamic landscape featuring diverse market shares, competitive pricing strategies, and a surge in new product launches. Key players are leveraging innovative approaches to capture market share, while pricing remains competitive to ensure accessibility and market penetration. The introduction of novel therapies has invigorated the market, with companies prioritizing strategic launches to maximize impact. This evolving scenario underscores the market's commitment to advancing therapeutic options and meeting unmet medical needs. Competition benchmarking reveals a robust rivalry, with leading firms vying for dominance through strategic alliances and mergers. Regulatory influences play a pivotal role, with stringent guidelines impacting market entry and development timelines. The United States and Europe remain at the forefront, setting regulatory standards that shape global market dynamics. Emerging markets, however, present untapped opportunities, as regulatory frameworks evolve. The market is poised for growth, driven by technological advancements and increased investment in research and development.

Geographical Overview:

The AR T-Cell therapy market is witnessing substantial growth across various regions, each exhibiting unique dynamics. North America leads, propelled by robust research and development activities and significant healthcare investments. The presence of leading biotech firms and advanced healthcare infrastructure further accelerates market expansion. Europe follows closely, with strong government support and funding for innovative therapies fostering a conducive environment. The region's focus on personalized medicine and advanced healthcare solutions enhances its market potential. In Asia Pacific, the market is rapidly growing, driven by increasing healthcare expenditures and rising awareness of advanced therapies. Countries like China and India are emerging as key players, with substantial investments in biotechnology research. Latin America and the Middle East & Africa show promising growth potential. Latin America benefits from rising healthcare investments, while the Middle East & Africa are recognizing the importance of innovative therapies in addressing unmet medical needs and driving healthcare advancements.

The AR T-Cell therapy market is increasingly influenced by global tariffs and geopolitical dynamics, particularly in East Asia. Japan and South Korea are navigating US-China trade tensions by fostering domestic biotech innovation and enhancing cross-border collaborations. China's strategic pivot towards self-reliance in biopharma is evident in its increased R&D investments and regulatory reforms. Taiwan, while a hub for semiconductor manufacturing, is diversifying into biotech to mitigate geopolitical risks. The parent market is experiencing robust growth, driven by advancements in personalized medicine and increasing cancer prevalence. By 2035, the market is anticipated to mature through regional partnerships and technological breakthroughs. Meanwhile, Middle East conflicts contribute to volatile energy prices, indirectly affecting global supply chain costs and operational efficiencies in the biopharma sector.

Key Trends and Drivers:

The AR T-Cell therapy market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. A key trend is the increasing focus on precision therapies tailored to individual patient profiles, enhancing treatment efficacy and minimizing adverse effects. This trend is supported by breakthroughs in genetic engineering and synthetic biology, enabling more targeted and effective therapies. The growing prevalence of cancer and other chronic diseases is a significant driver, propelling the demand for innovative treatment options like AR T-Cell therapies. Additionally, regulatory agencies are increasingly facilitating accelerated approval pathways, recognizing the potential of these therapies to address unmet medical needs. This regulatory support is fostering an environment conducive to rapid innovation and commercialization. Investment in research and development is another critical driver, with both public and private sectors channeling substantial resources into AR T-Cell therapy projects. Collaborations between biotech companies and academic institutions are accelerating the pace of discovery and development. Furthermore, the expanding healthcare infrastructure in emerging markets is opening new avenues for market penetration, presenting lucrative opportunities for companies poised to meet the growing demand for advanced therapeutic solutions.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Autologous T-Cell Therapy
    • 4.1.2 Allogeneic T-Cell Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 CAR T-Cells
    • 4.2.2 TILs (Tumor Infiltrating Lymphocytes)
    • 4.2.3 TCR (T-Cell Receptor) Therapy
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Clinical Trial Services
    • 4.3.2 Manufacturing Services
    • 4.3.3 Logistics and Supply Chain Services
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Editing
    • 4.4.2 CRISPR
    • 4.4.3 Lentiviral Vectors
    • 4.4.4 Retroviral Vectors
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Hematology
    • 4.5.3 Solid Tumors
    • 4.5.4 Infectious Diseases
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Research Institutes
    • 4.6.3 Biopharmaceutical Companies
    • 4.6.4 Academic and Research Institutes
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Cell Isolation
    • 4.7.2 Cell Activation
    • 4.7.3 Gene Modification
    • 4.7.4 Cell Expansion
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Research
    • 4.9.2 Clinical Trials
    • 4.9.3 Commercialization
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Personalized Medicine
    • 4.10.2 Off-the-shelf Products

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Adaptimmune Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Atara Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Autolus Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bellicum Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Cellectis
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Celyad Oncology
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Fate Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Genocea Biosciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iovance Biotherapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Kiadis Pharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Kite Pharma
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Marker Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Mustang Bio
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Poseida Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Precision Bio Sciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Sorrento Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Tessa Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Tmunity Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Triumvira Immunologics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 ZIOPHARM Oncology
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us